In our last issue, we discussed ways for rheumatology practice managers, physicians, healthcare professionals, and patients to get involved and raise awareness about concerns surrounding the Medicare Part B Drug Payment Model Proposed Rule by the Centers for Medicare & Medicaid Services (CMS). Andrea and I wanted to share our Washington, DC, experience and encourage our membership to continue to oppose the Part B Drug Demonstration Project.
As we move into another year, it is important now more than ever for medical practices to ensure that they have a robust Health Insurance Portability and Accountability Act (HIPAA) compliance program in place. In 2009, the Office for Civil Rights (OCR) was appointed as the enforcement arm for HIPAA, and with that appointment came a mandate by Congress to begin auditing entities that fall under the HIPAA rules.
The negative effects of smoking and obesity are present in both sexes, but were more robust in women according to the results of a study presented at the 2016 European League Against Rheumatism Annual Congress.
- Medicare Health, Drug Program Payment and Policy Updates for 2017 Finalized
- CMS Increases Transparency of Medicare Part B Program
- Part B Faces Backlash from the Rheumatology Community
Healthcare providers in private practice often ask whether they should form a legal entity. You need to decide if you want to “incorporate,” and to determine which business entity is best for you based on your individual needs and goals. This article will highlight why you should consider forming a legal entity, as well as review some important aspects associated with the most common legal business entities available.
With the 2016 National Organization of Rheumatology Managers (NORM) Conference happening in Mobile, AL, on September 16 and 17, we wanted to learn more about our host town. We sat down with Stacy Hamilton, Vice President of Marketing and Communications for Visit Mobile, so she could give us the inside scoop on how to act like a local in the Azalea City.
The following clinical trials represent a selection of key clinical trials that are currently recruiting patients with gout for inclusion in investigations of new therapies and regimens of available therapies for patients with gout. Each clinical trial description includes the NLM Identifier to be used as a reference for Clin icalTrials.gov. The information below can help rheumatology practice managers and providers direct their eligible patients to one of these clinical trials.
Results 1 - 7 of 7